Agilent Technologies has a Cash Ratio of 1.08. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Agilent Technologies's Cash Ratio or its related term are showing as below:
FRA:AG8'
s Cash Ratio Range Over the Past 10 Years
Min: 0.57 Med: 1.41 Max: 2.43
Current: 1.08
During the past 13 years, Agilent Technologies's highest Cash Ratio was 2.43. The lowest was 0.57. And the median was 1.41.
FRA:AG8's Cash Ratio is ranked better than 51.5% of 233
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.05
vs FRA:AG8: 1.08
Agilent Technologies Cash Ratio Historical Data
The historical data trend for Agilent Technologies's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Agilent Technologies's Cash Ratio
For the Diagnostics & Research subindustry, Agilent Technologies's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agilent Technologies's Cash Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Agilent Technologies's Cash Ratio falls into.
Agilent Technologies Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Agilent Technologies's Cash Ratio for the fiscal year that ended in Oct. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agilent Technologies (FRA:AG8) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Agilent Technologies Cash Ratio Related Terms
Thank you for viewing the detailed overview of Agilent Technologies's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Agilent Technologies (FRA:AG8) Business Description
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab (consisting of consumables and services related to life science and applied tools), and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. and China representing the largest country concentrations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:AG8 has been successfully added to your 